Premier Research Group announces the re-branding of its Medical Device business unit to D-TARGET, a Premier Research Company. With the continued growth in clinical development activity driven by rising regulatory and commercial demands in the medical device industry, Premier Research recognizes this sector has specific needs.
D-TARGET was founded in 1997 and acquired by Premier Research in 2007. By reintroducing the name, Premier Research reinforces its focus on this sector and highlights the capability, expertise, and experience gained by its staff operating as a dedicated Medical Device Contract Research Organization.
This division offers a team of medical device specialists with experience in the European Union and North America. D-TARGET’s staff is located in more than 30 countries with primary offices in Yverdon, Switzerland and Boston, Massachusetts. Sponsors directly benefit from regional employees with their knowledge of the local clinical research environment and ability to communicate with investigators and regulatory bodies in their own local language.
D-TARGET continues to offer a total life cycle partnership for developers of medical device and combination products, ranging from: strategic and tactical advisory services, clinical trial set-up, and clinical trial operations through to post marketing surveillance and registry support. In conjunction with the clinical operational staff, D-TARGET has specialist support groups dedicated to: regulatory affairs, ethical committee, competent authority, and country specific submissions, protocol writing, statistical analysis, and data management, thereby enabling our teams to meet the full range of needs of medical device developers worldwide.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.